Peramivir
Peramivir is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- FDA approved for uncomplicated influenza in patients 2 years and older with symptoms present less then 2 days.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Treatment of influenza for hospitalized adult and pediatric patients for whom therapy with an IV anti-influenza drug is needed.
- Limited data available to support efficacy in complicated influenza, or influenza requiring hospitalization or influenza > 48h duration[7].
- Peramivir can be considered for treatment failure occurring with use of currently approved anti-influenza drugs (e.g., oseltamivir and zanamivir) and in patients who are unable to take oral or inhaled anti-viral therapy.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- FDA approved for uncomplicated influenza in patients 2 years and older with symptoms present less then 2 days.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Treatment of influenza for hospitalized adult and pediatric patients for whom therapy with an IV anti-influenza drug is needed.
- Limited data available to support efficacy in complicated influenza, or influenza requiring hospitalization or influenza > 48h duration[7].
- Peramivir can be considered for treatment failure occurring with use of currently approved anti-influenza drugs (e.g., oseltamivir and zanamivir) and in patients who are unable to take oral or inhaled anti-viral therapy.
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2022 Unbound Medicine, Inc. All rights reserved